Communiqués Scienture Holdings, Inc.

Actions

SCNX

US80880X2036

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
3,760 ^USD	-2,59 %		-5,29 %	-70,51 %

02/10	Scienture Holdings, Inc. annonce l’ajout d’Arbli? aux formulaires de trois centres médicaux universitaires et hôpitaux pédiatriques américains	CI
01/10	Les plus fortes baisses avant l’ouverture	MT

Communiqués

05/10	SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals	AQ
02/10	SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals	AQ
30/09	Scienture Holdings, Inc. Announces Reverse Stock Split	AQ
22/09	SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner	AQ
09/09	SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026	AQ
14/08	SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance	AQ
14/08	Scienture Holdings: Q2 Earnings Snapshot	AQ
12/08	SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray	AQ
09/07	SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers	AQ
18/06	SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide	AQ
09/06	SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team	AQ
04/06	SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC	AQ
02/06	SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041	AQ
18/05	SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion	AQ
15/05	Scienture Holdings: Q1 Earnings Snapshot	AQ
07/05	Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline	AQ
06/05	SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041	AQ
15/04	Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement	AQ
06/04	Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead	AQ
30/03	Scienture Holdings: Q4 Earnings Snapshot	AQ
30/03	SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update	AQ
11/03	SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions	AQ
03/02	SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium	AQ
14/01	SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment	AQ
22/12	SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA	AQ